Opicapone: all 42 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• OpiCapone Effect on Motor Fluctuations and pAiNCompletedNCT04986982Phase 4Results posted
• Dosage Form Proportionality of Opicapone To-Be-Marketed FormulationCompletedNCT02305329Phase 1Results posted
• Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy VolunteersCompletedNCT02305277Phase 1Results posted
• The Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsCompletedNCT02170376Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/BenserazideCompletedNCT02169895Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/CarbidopaCompletedNCT02169479Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/BenserazideCompletedNCT02169466Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/CarbidopaCompletedNCT02169453Phase 1Results posted
• Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of WarfarinCompletedNCT02169440Phase 1Results posted
• An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and MetabolitesCompletedNCT02169427Phase 1Results posted
• Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa PharmacokineticsCompletedNCT02169414Phase 1Results posted
• Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic ImpairmentCompletedNCT02101190Phase 1Results posted
• Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young SubjectsCompletedNCT02092168Phase 1Results posted
• Comparative Bioavailability Study of BIA 9-1067 25 mg CapsulesCompletedNCT02071823Phase 1Results posted
• Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067CompletedNCT02071810Phase 1Results posted
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonCompletedNCT01568073Phase 3Results posted
• A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067CompletedNCT01568034Phase 2Results posted
• Effect of BIA 9-1067 on the Pharmacokinetics of RepaglinideCompletedNCT01536366Phase 1Results posted
• Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/BenserazideCompletedNCT01533116Phase 1Results posted
• Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/CarbidopaCompletedNCT01533077Phase 1Results posted
• Effect of Rasagiline on BIA 9-1067 PharmacokineticsCompletedNCT01532141Phase 1Results posted
• Effect of BIA 9-1067 on Rasagiline PharmacokineticsCompletedNCT01532128Phase 1Results posted
• Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsCompletedNCT01520987Phase 1Results posted
• A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male SubjectsCompletedNCT01520727Phase 1Results posted
• Study of BIA 9-1067 to Investigate Its Effect on Levodopa PharmacokineticCompletedNCT01519284Phase 1Results posted
• Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and MetabolitesCompletedNCT01515891Phase 1Results posted
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.CompletedNCT01227655Phase 3Results posted
• Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's DiseaseCompletedNCT06432309Not applicable
• eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.CompletedNCT04990284Phase 4
• OpicApone Sleep dISorderCompletedNCT04986995Phase 4
• Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)CompletedNCT04978597Phase 3
• A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PDCompletedNCT04821687Phase 4
• Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)CompletedNCT04265027Phase 1
• Relative Bioavailability and Bioequivalence of OpicaponeCompletedNCT03820037Phase 1
• A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.CompletedNCT03496870Phase 1
• Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067CompletedNCT03119194Phase 1
• Effect of Food on OpicaponeCompletedNCT03116308Phase 1
• Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeCompletedNCT03116295Phase 1
• AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine TherapyTerminatedNCT03092635Phase 1
• Efficacy and Safety of Opicapone in Clinical PracticeCompletedNCT02847442Phase 4
• Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical TrialCompletedNCT01851850Phase 3
• Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and WomenCompletedNCT01532115Phase 1

← Opicapone overview